张成宁, 姚思妤, 杨龙, 万淳钰, 陈英, 张强, 王学清. 胶体二氧化硅对幼年小鼠肠道屏障和黏膜免疫的影响J. 药学学报, 2025, 60(6): 1901-1910. DOI: 10.16438/j.0513-4870.2025-0224
引用本文: 张成宁, 姚思妤, 杨龙, 万淳钰, 陈英, 张强, 王学清. 胶体二氧化硅对幼年小鼠肠道屏障和黏膜免疫的影响J. 药学学报, 2025, 60(6): 1901-1910. DOI: 10.16438/j.0513-4870.2025-0224
ZHANG Cheng-ning, YAO Si-yu, YANG Long, WAN Chun-yu, CHEN Ying, ZHANG Qiang, WANG Xue-qing. Effects of colloidal silicon dioxide on intestinal barrier and mucosal immunity in childhood miceJ. Acta Pharmaceutica Sinica, 2025, 60(6): 1901-1910. DOI: 10.16438/j.0513-4870.2025-0224
Citation: ZHANG Cheng-ning, YAO Si-yu, YANG Long, WAN Chun-yu, CHEN Ying, ZHANG Qiang, WANG Xue-qing. Effects of colloidal silicon dioxide on intestinal barrier and mucosal immunity in childhood miceJ. Acta Pharmaceutica Sinica, 2025, 60(6): 1901-1910. DOI: 10.16438/j.0513-4870.2025-0224

胶体二氧化硅对幼年小鼠肠道屏障和黏膜免疫的影响

Effects of colloidal silicon dioxide on intestinal barrier and mucosal immunity in childhood mice

  • 摘要: 本研究旨在探究胶体二氧化硅纳米颗粒Aerosil 200 (A200) 对幼年小鼠肠道屏障及黏膜免疫的影响。3周龄BALB/c小鼠持续1周灌胃给予不同剂量(20、50、200 mg·kg-1) 的A200, 综合评估其肠道形态、屏障功能、免疫细胞表型及口服耐受能力。肠道形态研究结果显示, 不同剂量A200未引起明显肠道病理损伤, 但200 mg·kg-1剂量组导致回肠绒毛长度增加、隐窝深度降低。屏障功能研究结果表明, 200 mg·kg-1剂量组导致回肠ZO-1蛋白表达上调而结肠ZO-1下调; 不同剂量组肠道干细胞标志物Lgr5无显著变化, 200 mg·kg-1组回肠Mucin-2升高、lysozyme减少。免疫细胞表型研究结果表明, 20、50 mg·kg-1组的肠系膜淋巴结的Treg、Th2细胞表型占比无明显变化, 200 mg·kg-1组Treg和Th2细胞比例增加, 但血清及回肠炎症因子(TNF-α、IL-6) 水平未受影响。口服耐受实验结果表明, 不同剂量A200未改变OVA特异性IgG、IgG1、IgG2a抗体水平。所有动物实验经北京大学医学部实验动物科研伦理委员会审查(批准号: BCJB0076), 符合实验动物伦理相关规范。综上, 3种剂量A200对幼年小鼠肠道屏障及黏膜免疫总体安全, 但高剂量可能通过调节上皮屏障相关蛋白及免疫细胞表型产生潜在影响。这些结果为儿童用药安全性评估提供参考。

     

    Abstract: This study aimed to investigate the effects of colloidal silica nanoparticles Aerosil 200 (A200) on intestinal barrier and mucosal immunity in childhood mice. Three-week-old BALB/c mice were administered A200 (20, 50, 200 mg·kg-1) via gavage for 7 days. Intestinal morphology, barrier function, immune cell phenotypes, and oral tolerance were systematically evaluated. Histopathological analysis of intestinal morphology revealed that no obvious pathological damage in the intestine. However, 200 mg·kg-1 A200 increased ileal villus length, reduced crypt depth. Functional assessments of the intestinal barrier demonstrated that 200 mg·kg-1 A200 upregulated ZO-1 in the ileum but downregulated it in the colon; The intestinal stem cell marker Lgr5 remained unchanged, while Mucin-2 increased and lysozyme decreased in the ileum. Analysis of immune cell phenotypes revealed that the 200 mg·kg-1 group exhibited elevated proportions of Treg and Th2 cells in the mesenteric lymph nodes, while serum and intestinal levels of TNF-α and IL-6 remained unaffected. Oral tolerance assays revealed no alteration in OVA-specific IgG, IgG1, or IgG2a antibody levels. Animal welfare and the animal experimental protocols were strictly consistent with related ethics regulations of Peking University Health Science Center (Approval No.: BCJB0076). In conclusion, A200 is generally safe for childhood mice but may modulate epithelial barrier proteins and immune cell phenotypes at high doses, which may provide insights into its pediatric application.

     

/

返回文章
返回